TABLE 2.
Method | Pro(s) | Con(s) | References |
---|---|---|---|
Intermittent | Shortens treatment, reduces dosage | Emergence of resistance, requires supervision | 65–68 |
High dose | Reduces visits to clinicians, eradicates persisters | Toxicity, tolerance | 71, 72 |
Resuscitation | Tackles persistent cells directly | Uncontrolled resuscitation might cause relapse | 73, 74 |
Immunotherapy adjuvants | Promising approach, reduces toxicity | Unexpected adverse reactions, variable success, more studies required | 75–78 |